Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Retained Earnings (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Retained Earnings readings, the most recent being $8.8 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 16.85% to $8.8 million in Q1 2026 year-over-year; TTM through Jan 2026 was $8.8 million, a 16.85% decrease, with the full-year FY2025 number at $10.5 million, up 3914.63% from a year prior.
  • Retained Earnings hit $8.8 million in Q1 2026 for Pharma-Bio Serv, down from $10.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $15.7 million in Q1 2023 to a low of $28619.0 in Q3 2022.
  • Median Retained Earnings over the past 5 years was $10.5 million (2025), compared with a mean of $7.6 million.
  • Biggest five-year swings in Retained Earnings: crashed 99.87% in 2022 and later soared 13092.37% in 2023.
  • Pharma-Bio Serv's Retained Earnings stood at $238152.0 in 2022, then soared by 6137.12% to $14.9 million in 2023, then crashed by 98.23% to $262380.0 in 2024, then skyrocketed by 3914.63% to $10.5 million in 2025, then decreased by 15.99% to $8.8 million in 2026.
  • The last three reported values for Retained Earnings were $8.8 million (Q1 2026), $10.5 million (Q4 2025), and $285577.0 (Q3 2025) per Business Quant data.